Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis

Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were launched in December 2020. Vaccination of patients with rheumatic diseases is recommended, as they are considered at higher risk of severe COVID-19 than the general population. Patients with rheumatic disease have lar...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartels, Lars Erik, Ammitzbøll, Christian, Andersen, Jakob Bøgh, Vils, Signe Risbøl, Mistegaard, Clara Elbæk, Johannsen, Anders Dahl, Hermansen, Marie-Louise From, Thomsen, Marianne Kragh, Erikstrup, Christian, Hauge, Ellen-Margrethe, Troldborg, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Observational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412379/
https://www.ncbi.nlm.nih.gov/pubmed/34476603
http://dx.doi.org/10.1007/s00296-021-04972-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412379/
https://www.ncbi.nlm.nih.gov/pubmed/34476603
http://dx.doi.org/10.1007/s00296-021-04972-7

Ejemplares similares